Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pibrentasvir - AbbVie

Next Previous
X
Search
Drug Profile

Pibrentasvir - AbbVie

Alternative Names: ABT-530

Latest Information Update: 28 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Antivirals; Benzimidazoles; Carbamates; Fluorobenzenes; Piperidines; Pyrrolidines
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 26 Jul 2022 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-experienced) in Australia, New Zealand, United Kingdom (PO) (AbbVie website, July 2022)
  • 26 Jul 2022 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive) in USA (PO) (AbbVie website, July 2022)
  • 26 Jul 2022 No development reported - Phase-II for Hepatitis C (Combination therapy, Treatment-naive, Treatment-experienced) in USA, Puerto Rico, New Zealand, Australia, Canada, France, Italy, Italy, Germany, Spain, United Kingdom, South Korea, Taiwan (PO) (AbbVie website, July 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top